Louisiana State Employees Retirement System Makes New $1.51 Million Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Louisiana State Employees Retirement System bought a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 64,500 shares of the biopharmaceutical company’s stock, valued at approximately $1,509,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TGTX. NBC Securities Inc. lifted its position in TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC bought a new position in shares of TG Therapeutics in the second quarter worth about $35,000. Blue Trust Inc. lifted its position in shares of TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 849 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in shares of TG Therapeutics during the third quarter valued at approximately $53,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of TG Therapeutics in the first quarter valued at approximately $58,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $25.06 on Friday. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58. TG Therapeutics, Inc. has a 12-month low of $7.17 and a 12-month high of $26.41. The firm has a fifty day moving average of $23.44 and a 200-day moving average of $19.89. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of 108.96 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The firm had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The company’s revenue was up 357.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.34) earnings per share. On average, equities research analysts forecast that TG Therapeutics, Inc. will post 0.13 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on TGTX shares. TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday. They set a “buy” rating and a $50.00 price objective on the stock. B. Riley lifted their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a research report on Wednesday, September 18th. Finally, The Goldman Sachs Group raised their price target on TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $34.43.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.